Long noncoding RNAs as biotargets in cisplatin-based drug resistance

Nadiah Abu, Kha Wai Hon, Shivapriya Jeyaraman, A. Rahman A. Jamal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Since its discovery, cisplatin has become the key drug in chemotherapy for cancers. Nevertheless, chemoresistance in cancers has become an impediment in using cisplatin for cancer treatment. The resistance toward cisplatin is multifaceted as it involves multiple cellular pathways. Ever since the knowledge of long noncoding RNAs as modulators of various molecular pathways came to light, the interest in the biological function of lncRNAs as biomarkers has increased dramatically. Numerous studies have reported the link between the dysregulation of lncRNAs and drug resistance in cancers. More importantly, several lncRNAs were found to be vital in regulating cisplatin resistance. Therefore, this review summarizes the recent efforts in linking between cisplatin resistance and different types of lncRNAs.

Original languageEnglish
Pages (from-to)3085-3095
Number of pages11
JournalFuture Oncology
Volume14
Issue number29
DOIs
Publication statusPublished - 1 Dec 2018
Externally publishedYes

Fingerprint

Long Noncoding RNA
Drug Resistance
Cisplatin
Neoplasms
Biomarkers
Drug Therapy
Pharmaceutical Preparations

Keywords

  • biomarker
  • cisplatin
  • lncRNA
  • noncoding RNA
  • platinum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Long noncoding RNAs as biotargets in cisplatin-based drug resistance. / Abu, Nadiah; Hon, Kha Wai; Jeyaraman, Shivapriya; A. Jamal, A. Rahman.

In: Future Oncology, Vol. 14, No. 29, 01.12.2018, p. 3085-3095.

Research output: Contribution to journalArticle

Abu, Nadiah ; Hon, Kha Wai ; Jeyaraman, Shivapriya ; A. Jamal, A. Rahman. / Long noncoding RNAs as biotargets in cisplatin-based drug resistance. In: Future Oncology. 2018 ; Vol. 14, No. 29. pp. 3085-3095.
@article{96cf1576a9be47918e3a8496073aa7a2,
title = "Long noncoding RNAs as biotargets in cisplatin-based drug resistance",
abstract = "Since its discovery, cisplatin has become the key drug in chemotherapy for cancers. Nevertheless, chemoresistance in cancers has become an impediment in using cisplatin for cancer treatment. The resistance toward cisplatin is multifaceted as it involves multiple cellular pathways. Ever since the knowledge of long noncoding RNAs as modulators of various molecular pathways came to light, the interest in the biological function of lncRNAs as biomarkers has increased dramatically. Numerous studies have reported the link between the dysregulation of lncRNAs and drug resistance in cancers. More importantly, several lncRNAs were found to be vital in regulating cisplatin resistance. Therefore, this review summarizes the recent efforts in linking between cisplatin resistance and different types of lncRNAs.",
keywords = "biomarker, cisplatin, lncRNA, noncoding RNA, platinum",
author = "Nadiah Abu and Hon, {Kha Wai} and Shivapriya Jeyaraman and {A. Jamal}, {A. Rahman}",
year = "2018",
month = "12",
day = "1",
doi = "10.2217/fon-2018-0303",
language = "English",
volume = "14",
pages = "3085--3095",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "29",

}

TY - JOUR

T1 - Long noncoding RNAs as biotargets in cisplatin-based drug resistance

AU - Abu, Nadiah

AU - Hon, Kha Wai

AU - Jeyaraman, Shivapriya

AU - A. Jamal, A. Rahman

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Since its discovery, cisplatin has become the key drug in chemotherapy for cancers. Nevertheless, chemoresistance in cancers has become an impediment in using cisplatin for cancer treatment. The resistance toward cisplatin is multifaceted as it involves multiple cellular pathways. Ever since the knowledge of long noncoding RNAs as modulators of various molecular pathways came to light, the interest in the biological function of lncRNAs as biomarkers has increased dramatically. Numerous studies have reported the link between the dysregulation of lncRNAs and drug resistance in cancers. More importantly, several lncRNAs were found to be vital in regulating cisplatin resistance. Therefore, this review summarizes the recent efforts in linking between cisplatin resistance and different types of lncRNAs.

AB - Since its discovery, cisplatin has become the key drug in chemotherapy for cancers. Nevertheless, chemoresistance in cancers has become an impediment in using cisplatin for cancer treatment. The resistance toward cisplatin is multifaceted as it involves multiple cellular pathways. Ever since the knowledge of long noncoding RNAs as modulators of various molecular pathways came to light, the interest in the biological function of lncRNAs as biomarkers has increased dramatically. Numerous studies have reported the link between the dysregulation of lncRNAs and drug resistance in cancers. More importantly, several lncRNAs were found to be vital in regulating cisplatin resistance. Therefore, this review summarizes the recent efforts in linking between cisplatin resistance and different types of lncRNAs.

KW - biomarker

KW - cisplatin

KW - lncRNA

KW - noncoding RNA

KW - platinum

UR - http://www.scopus.com/inward/record.url?scp=85058279580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058279580&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0303

DO - 10.2217/fon-2018-0303

M3 - Article

VL - 14

SP - 3085

EP - 3095

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 29

ER -